Biomarkers for liver fibrosis: Advances, advantages and disadvantages;Biomarcadores para fibrosis hepática, avances, ventajas y desventajas

Revista de Gastroenterologia de Mexico

Volumn 79, Issue 3, 2014, Pages 187-199

  Cequera, A ^a   De Garcia Leon Mendez M C ^a  

^a HOSPITAL GENERAL DE MÉXICO   (Mexico)

Author keywords

Elastography; FibroScan; Fibrosis biomarkers; Fibrotest; Liver biopsy; Liver cirrhosis

Indexed keywords

BIOLOGICAL MARKER;

BIOPSY; BLOOD; ELASTOGRAPHY; HUMAN; LIVER CIRRHOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING;

BIOMARKERS; BIOPSY; ELASTICITY IMAGING TECHNIQUES; HUMANS; LIVER CIRRHOSIS; MAGNETIC RESONANCE IMAGING;

EID: 84918564913     PISSN: 03750906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rgmx.2014.05.003     Document Type: Short Survey

References (83)

1. Rojkind M, Greenwel P. The extracellular matrix and the liver. En: Arias IM, Boyer JL, Fausto N, et al., editores. The liver: Biology and pathology. 3th ed New York: Raven Press; 1994. p. 843-68.
2. Bedossa P, Paradis V. Liver extracellular matrix in health and disease. J Pathol. 2003;200:504-15.
3. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem. 2000;275:2247-50.
4. Sistema Nacional de Información en Salud (SINAIS). Informe de funciones generales de la Secretaría de Salud, 2008 [consultado 14 Feb 2013]. Disponible en: http://www.sinais.salud.gob.mx/ mortalidad/index.html
5. Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12:3682-94.
6. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatol. 1996;24:289-93.
7. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97:2614-8.
8. Colloredo G, Guido M, Sonzogni A, et al. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: The smaller the sample, the milder the disease. J Hepatol. 2003;39:239-44.
9. Siddique I, El-Naga HA, Madda JP, et al. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol. 2003;38:427-32.
10. Janiec DJ, Jacobson ER, Freeth A, et al. Histologic variation of grade and stage of non-alcoholic fatty liver disease in liver biopsies. Obes Surg. 2005;15:497-501.
11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatol. 2003;38:1449-57.
12. Piccinino F, Sagnelli E, Pasquale G, et al. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68 276 biopsies. J Hepatol. 1986;2:165-73.
13. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatol. 2009;49:1017-44, http://dx.doi.org/10.1002/hep.22742.
14. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion. 2003;67:138-45.
15. West J, Card TR. Reduced mortality rates following elective percutaneous liver biopsies. Gastroenterology. 2010;139:1230-7. Publicación electrónica 12 Jun 2010.
16. Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: Clinical translation of molecular pathogenesis or based on liver dependent malfunction tests. Clin Chim Acta. 2007;381:107-13.
17. Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. J Clin Invest. 2007;117:539-48.
18. Plebani M, Burlina A. Biochemical markers of hepatic fibrosis. Clin Biochem. 1991;24:219-39.
19. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-302.
20. Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. J Dig Dis. 2009;10:7-14.
21. Baranova A, Lal P, Birerdinc A, et al. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91.
22. Gressner AM, Gao CF, Gressner OA. Non-invasive biomarkers for monitoring the fibrogenicprocess in liver: A short survey. World J Gastroenterol. 2009;15:2433-40.
23. Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis. 2006;15:149-59.
24. Haukeland JW, Schreiner LT, Lorgen I AST/ALT ratio provides prognostic information independently of Child-Pugh class, gender and age in non-alcoholic cirrhosis. Scand J Gastroenterology. 2008;43:1241-8.
25. Giboney PT. Mildly elevated liver transaminase levels in the asymptomatic patient. Am Fam Physician. 2005;71: 1105-10.
26. Green RM, Flamm S. AGA technical review on the evaluation of liver chemistry tests. Gastroenterology. 2002;123: 1367-84.
27. Giannini E, Risso D, Botta F Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163:218-24.
28. Croquet V, Vuillemin E, Ternisien C, et al. Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol. 2002;14:1133-41.
29. Pilette C, Oberti F, Aubé C, et al. Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol. 1999;31:867-73.
30. Jarcuska P, Janicko M, Veseliny E, et al. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411:1009-17.
31. Murawaki Y, Koda M, Okamoto K, et al. Diagnostic value of serum type iv collagen test in comparison with platelet count for predicting the fibrotic stage in patients with chronic hepatitis. J Gastroenterol Hepatol. 2001;16:777-81.
32. Kanzler S, Baumann M, Schirmacher P, et al. Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor beta. J Viral Hepat. 2001;8:430-7.
33. Lydatakis H, Hager IP, Kostadelou E, et al. Non-invasive markers to predict the liver fibrosis in non alcoholic fatty liver disease. Liver Int. 2006;26:864-71.
34. Greenlee KJ, Werb Z, Kheradmand F. Matrix metalloproteinases in lung: Multiple, multifarious, and multifaceted. Physiol Rev. 2007;87:69-98.
35. Mölleken C, Sitek B, Henkel C, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatol. 2009;49:1257-66.
36. Adams LA, George J, Burgianesi E, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2011;26:1536-43.
37. Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet. 2001;357:1069-75.
38. Lu LG, Zeng MD, Mao YM, et al. Relationship between clinical and pathologic findings in patients with chronic liver diseases. World J Gastroenterol. 2003;9:2796-800.
39. Nguyen-Khac E, Chatelain D, Tramier B, et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using FibroScan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther. 2008;28:1188-98.
40. Ahmad W, IJaz B, Gull S, et al. A brief review on molecular, genetic and imagingtechniques for HCV fibrosis evaluation. Virol J. 2011;8:53.
41. Dalla Piazza M, Amorosa VK, Localio R, et al. Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis. 2010;10:116.
42. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-36.
43. Wenwen J, Zhonghua L, Yongning X, et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: A leading metaanalysis. BMC Gastroenterol. 2012;12:14.
44. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez- Bauer E, et al. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002;36:986-92.
45. Guechot J, Lasnier E, Sturm N, et al. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta. 2010;411:86-91.
46. Adams LA, Bulsara M, Rossi E, et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51:1867-73.
47. Imbert-Bismut F, Messous D, Thibault V, et al. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibro- Test) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med. 2004;42:323-33.
48. Poynard T, Munteanu M, Deckmyn O, et al. Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: proof of concept and first application in a large population. J Hepatol. 2012;57:541-8.
49. Kim BK, Kim SU, Kim HS. Prospective validation of Fibro- Test in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7:e35825.
50. Munteanu M, Ratziu V, Morra R, et al. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis. 2008;17:187-91.
51. Fouad A, Sabry D, Ahmed R, et al. Comparative diagnostic study of biomarkers using FibroMaxTM and pathology for prediction of liver steatosis in patients with chronic hepatitis C virus infection: an Egyptian study. Int J Gen Med. 2013;6: 127-34.
52. Palmeri ML, Nightingale KR. Acoustic radiation force-based elasticity imaging methods. Interface Focus. 2011;1:553-64.
53. Vergniol J, Foucher J, Terrebonne E, et al. Noninvansive tests for fibrosis and liver stiffness predict 5 years outcomes of patients with chronic hepatitis C. Gastroenterology. 2011;140:1970-9, 1970.e1-3.
54. Nightingale K. Acoustic radiation force impulse (ARFI) imaging: A review. Curr Med Imaging Rev. 2011;7:328-39.
55. Kim SU, Choi GH, Han WK. What are "true normal" liver stiffness values using FibroScan? A prospective study in healthy living liver and kidney donors in South Korea. Liver Int. 2010;30:268-74.
56. Degos F, Perez P, Roche B, et al., FIBROSTIC study group. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53:1013-21.
57. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a metaanalysis. Gastroenterology. 2008;134:960-74.
58. Wong GL. Trasiente elastography: Kill two birds with one stone? World Hepatol. 2013;5:264-74.
59. Clouston AD, Jonsson JR, Powell EE. Steatosis as a cofactor in other liver diseases: Hepatitis C virus, alcohol, hemochromatosis, and others. Clin Liver Dis. 2007;11:173-89.
60. Sasso M, Beaugrand M, de Ledinghen V, et al. Controlled attenuation parameter (CAP): a novel VCTETM guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: Preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound Med Biol. 2010;36:1825-35.
61. Engelmann G, Gebhardt C, Wenning D, et al. Feasibility study and control values of transient elastography in healthy children. Eur J Pediatr. 2012;171:353-60.
62. De Lédinghen V, Vergniol J, Foucher J, et al. Feasibility of liver transient elastography with FibroScan using a new probe for obese patients. Liver Int. 2010;30:1043-8.
63. De Lédinghen V, Wong VW, Vergniol J, et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: Comparison between M and XL probe of FibroScan® . J Hepatol. 2012;56:833-9.
64. Wong VW, Vergniol J, Wong GL, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107:1862-71.
65. Forestier N, Gaus A, Herrmann E, et al. Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. J Gastrointestin Liver Dis. 2012;21:367-73.
66. Talwalkar JA, Yin M, Fidler JL, et al. Magnetic resonance imaging of hepatic fibrosis: Emerging clinical applications. Hepatology. 2008;47:332-42.
67. Naganawa S, Kawai H, Fukatsu H, et al. Diffusion-weighted imaging of the liver: Technical challenges and prospects for the future. Magn Reson Med Sci. 2005;4:175-86.
68. Yin M, Talwalkar JA, Glaser KJ, et al. Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastro Hep. 2007;5:1207-13.
69. Klatt D, Asbach P, Rump J, et al. In vivo determination of hepatic stiffness using steady-state free precision magnetic resonance elastography. Invest Radiol. 2006;41:841-8.
70. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008;135:32-40, http://dx.doi.org/10.1053/j.gastro.2008.03.076. Publicación electrónica 4 Abr 2008.
71. Fontana RJ, Dienstag JL, Bonkovsky HL, et al., HALT-C Trial Group. Serum fibrosis markers are associated with liver disease progression in nonresponder patients with chronic hepatitis C. Gut. 2010;59:1401-9.
72. Poynard T, Munteanu M, Imbert-Bismut F, et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem. 2004;10:1.
73. Park SH, Kim CH, Kim D, et al. Usefulness of multiple biomarkers for the prediction of significant fibrosis in chronic hepatitis B. J Clin Gastroenterol. 2011;45:361-5.
74. Willis BH. Spectrum bias-why clinicians need to be cautious when applying diagnostic test studies. Family Practice. 2008;25:390-6.
75. Goehring C, Perrier A, Morabia A. Spectrum bias: a quantitative and graphical analysis of the variability of medical diagnostic test performance. Statist Med. 2004;23:125-35.
76. Myers RP, Crotty P, Pomier-Layrargues G, et al. Prevalence, risk factors and causes of discordance in fibrosis staging by transient elastography and liver biopsy. Liver Int. 2010;30: 1471-80.
77. Fraquelli M, Rigamonti C, Casazza G, et al. Etiology-related determinants of liver stiffness values in chronic viral hepatitis Bor C J Hepatol. 2011;54:621-8.
78. Wells PN, Liang HD. Medical ultrasound: imaging of soft tissue strain and elasticity. J R Soc Interface. 2011;8:1521-49.
79. Callewaert N, Vlierberghe HV, Hecke AV, et al. Non invasive diagnosis of liver cirrhosis using DNA sequence-based total serum protein glycomics. Nat Med. 2004;10:429-34.
80. Blomme B, Van Steenkiste C, Callewaert N, et al. Alteration of protein glycosylation in liver diseases. J Hepatol. 2009;50:592-603.
81. Kuno A, Ikehara Y, Tanaka Y. A serum ''sweet-doughnut'' protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065.
82. Younossi ZM, Baranova A, Stepanova M, et al. Phosphoproteomic biomarkers predicting histologic nonalcoholic steatohepatitis and fibrosis. J Proteome Res. 2010;9:3218-24.
83. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med. 2013;158:807-20.